[ad_1]
Japan’s Ricoh Co. stated Tuesday that it’s going to enter the drug contract growth and manufacturing enterprise by buying a U.S. startup engaged in superior drugs.
Ricoh hopes that its synthetic intelligence and different applied sciences will assist assist the event of medication utilizing messenger RNA and induced pluripotent stem, or iPS, cells. The corporate expects the enterprise to change into a major income supply on a par with its workplace tools enterprise.
Unable to view this text?
This might be because of a battle along with your ad-blocking or safety software program.
Please add japantimes.co.jp and piano.io to your listing of allowed websites.
If this doesn’t resolve the difficulty or you might be unable so as to add the domains to your allowlist, please see out this assist web page.
We humbly apologize for the inconvenience.
In a time of each misinformation and an excessive amount of info, high quality journalism is extra essential than ever.
By subscribing, you may assist us get the story proper.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
[ad_2]
Source link
